Alzheimer’s Disease

Shares of clinical-stage biotech company NeuroSense Therapeutics Ltd (NASDAQ: NRSN) are ripping higher Thursday morning after the company reported positive final results from its Alzheimer's biomarker study. What Happened: Preliminary results from a study evaluating the potential...

Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. (OTC: ESALY) announced late on Tuesday positive Phase 3 results for their second-generation Alzheimer's treatment candidate lecanemab. What Happened: Biogen-Eisai’s late-stage trial would provide “strongly...

U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab. The Decision: Wall Street analysts and industry observers are divided on its chances of approval. Some analysts are...

Biogen Inc (NASDAQ: BIIB) shares are up sharply Friday after the company announced a delay in the FDA decision for its Alzheimer's treatment candidate, aducanumab. What Happened: The FDA has extended the review period for the biologic license application for aducanumab by three months, Biogen...

Shares of clinical-stage pharmaceutical company vTv Therapeutics Inc. (NASDAQ: VTVT) surged 50 percent Wednesday morning. What Happened The company is engaged in the research and development of treatments for Alzheimer’s disease and diabetes. This week, it announced the delivery of an...

Pain Therapeutics, Inc. (NASDAQ: PTIE) is a micro-cap company that has developed several drug candidates, such as an abuse-resistant hydromorphone, an abuse-resistant hydrocodone and an antibody for metastatic melanoma. What Happened Pain Therapeutics has been awarded a research grant of...

You've probably heard this before. As early as 2008, several reports, including one published in Molecular Pharmaceutics, began proposing various therapeutic pathways by which cannabinoids could treat Alzheimer’s Disease patients, but none were proven. In 2014, a group of scientists made a...